Epizyme reported $264.16M in Assets for its second fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Assets Change
Agios Pharmaceuticals AGIO:US $ 1252.47M 83.39M
Amarin AMRN:US $ 973.24M 0.47M
Amgen AMGN:US $ 59294M 98M
Avrobio Inc AVRO:US $ 146.24M 29.1M
Biogen BIIB:US $ 25081.4M 1467M
Bluebird Bio BLUE:US $ 573.59M 82.52M
Cerulean Pharma CERU:US $ 49.19M 6.62M
Daiichi Sankyo 4568:JP Y 2294549M 73147M
Eisai 4523:JP Y 1272871M 33556M
Epizyme EPZM:US $ 264.16M 48.03M
Exelixis EXEL:US $ 2881.4M 227.29M
Gilead Sciences GILD:US $ 62870M 210M
Glaxosmithkline GSK:US $ 89045M 644M
GlaxoSmithKline GSK:LN 89045M 644M
Karyopharm Therapeutics KPTI:US $ 256.48M 37.56M
Macrogenics MGNX:US $ 218.04M 53.4M
Mirati Therapeutics MRTX:US $ 1279.79M 141.51M
Novartis NOVN:VX SF 122910M 2308M
Novartis NVS:US $ 122910M 2308M
Regeneron Pharmaceuticals REGN:US $ 27205.8M 857.1M
Seattle Genetics SGEN:US $ 3630.34M 13.65M
Spectrum Pharmaceuticals SPPI:US $ 79.43M 20.62M
Vertex Pharmaceuticals VRTX:US $ 15582.2M 1326.1M
Xencor XNCR:US $ 851.32M 6.6M